吉西他滨联合奥沙利铂在晚期复发上皮细胞性卵巢癌临床疗效观察  

作　　者：赵兴[1] 全信强[1] 

机构地区：[1]大英县人民医院,四川遂宁629300

出　　处：《今日健康》2015年第10期12-12,186,共2页

摘　　要：目的探讨吉西他滨联合奥沙利铂在晚期复发上皮细胞性卵巢癌临床疗效观察。方法：回顾性研究2010年10月至2015年3月，19例晚期复发卵巢癌患者应用吉西他滨联合奥沙利铂化疗的临床疗效观察。化疗方法，注射吉西他滨1000mg／m2，静脉滴注，第1天、第8天；奥沙利铂130mg／m2静脉滴注，第1天；将整个疗程划分为四个周期，每个周期21天，连续治疗二个周期后观察疗效。通过对19名此种患者进行四个周期的化疗结果表明；进行化疗后出现如下反应的患者数量分别为CR0例、PR9例、SD7例、PD3例。其中主要的反应为骨髓抑制，并使得白细和血小板都明显减少分别减少比例57％和26％，且主要是中度。消化道和神经毒性不良反应率分别为63％和15％，也为轻度。对这些不良反应适当治疗都在短时间恢复。结论：吉西他滨联合奥沙利铂治疗晚期复发上皮细胞性卵巢癌有明显的疗效，不良反应较轻且很容易恢复。Objective To observe the clinical efficacy of gemcitabine combined with oxaliplatin in advanced epithelial ovarian cancer recurrence. Methods： a retrospective study in October 2010 to 2015 years March, 19 cases of the clinical curative effect of chemotherapy for advanced and recurrent ovarian cancer patients were treated with gemcitabine combined with oxaliplatin observed. Chemotherapy of gemcitabine 1000 mg / m2, intravenous infusion, day 1, the 8 days; oxaliplatin 130 mg / m2 intravenously, the 1 day; every 21 days for a period, QD for 4 cycles, after every two cycles efficacy evaluation. Results 19 patients with advanced recurrent ovarian cancer were scheduled to complete 4 cycles of chemotherapy; all patients can evaluate the efficacy, including CR 0 cases, PR 9 cases, SD 7 cases, PD 3 cases. The main adverse reactions were bone marrow suppression, which accounted for 57.8% of the reduction, the reduction of blood platelets was 26.3%, I to the second degree, the incidence of adverse reactions in the digestive tract was 63.1%, the incidence of peripheral neurotoxicity was 15.7%, and the I was I. Adverse reactions were treated with symptomatic treatment, and soon recovered. Conclusion the curative effect of gemcitabine combined with oxaliplatin in advanced and recurrent epithelial ovarian cancer, with mild adverse reactions.

关 键 词：卵巢肿瘤 吉西他滨 奥沙利铂 

分 类 号：R730.3[医药卫生—肿瘤]